An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia : An I-BFM-FLOW-Network Report

Simple item page
dc.contributor.authorMaurer-Granofszky, Margarita
dc.contributor.authorNikulshin, Sergey
dc.contributor.authorI-BFM-FLOW
dc.date.accessioned2022-01-18T14:35:01Z
dc.date.available2022-01-18T14:35:01Z
dc.date.issued2021-12-06
dc.description.abstractMonitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning maturation program, (ii) obligatory participation in external QA programs (spiked sample send around, United Kingdom National External Quality Assessment Service (UK NEQAS)), (iii) regular participation in list-mode-data (LMD) file ring trials (FCM data file send arounds), and (iv) surveys of independent data derived from trial results. We demonstrate that the training of laboratories using experienced twinning partners, along with continuous educational feedback significantly improves the performance of laboratories in detecting and quantifying MRD in pediatric ALL patients. Overall, our extensive education and quality control program improved inter-laboratory concordance rates of FCM-MRD assessments and ultimately led to a very high conformity of risk estimates in independent patient cohorts.en
dc.description.statusPeer reviewed
dc.format.extent2007212
dc.identifier.citationMaurer-Granofszky, M, Nikulshin, S & I-BFM-FLOW 2021, 'An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia : An I-BFM-FLOW-Network Report', Cancers, vol. 13, no. 23, 6148. https://doi.org/10.3390/cancers13236148
dc.identifier.doi10.3390/cancers13236148
dc.identifier.issn2072-6694
dc.identifier.otherPubMedCentral: PMC8656726
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/7224
dc.language.isoeng
dc.relation.ispartofCancers
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectacute lymphoblastic leukemia
dc.subjectminimal residual disease
dc.subjectflow cytometry
dc.subjectquality control program
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.titleAn Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia : An I-BFM-FLOW-Network Reporten
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
An_Extensive_Quality_Control_and_Quality_Assurance.pdf
Size:
1.91 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure